Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.
Réglementation et droit · 18/12/20151 min de lecture
Prospective Grant of Exclusive License: Development of a Small Molecule Farnesoid X Receptor Inhibitor
Traduction automatique locale · Langue originale de la source
Résumé
This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Cancer Institute (NCI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the following U.S. Patents and Patent Applications to Heliome Biotech, Inc. ("Heliome") located in New York, NY, USA. Intellectual Property:
Langue originale de la source: Federal Register — All DocumentsOuvrir le communiqué original →